BMO reiterates Trevi Therapeutics stock rating after rival study fails
BMO Capital reiterated an Outperform rating and $36.00 price target for Trevi Therapeutics (TRVI) after a competitor's trial failed. The stock is down ~8% over the past week. Trevi's drug candidate, Haduvio, has central and peripheral activity, with clinical readouts expected in late 2027. The company reported a wider-than-expected Q2 2026 loss but has sufficient cash to fund operations until 2030, according to the company.
How this was made
The 30-second read
Why it matters
The combined analyst upgrades and competitor setback provide fresh catalyst for TRVI, likely prompting buying interest.
Market read
Analyst upgrades and competitor failure create a short‑term bullish catalyst for Trevi Therapeutics.
What to watch
Potential regulatory delays for Trevi's own candidates and cash runway concerns beyond 2030.
Background
Analyst houses reaffirmed Outperform ratings on Trevi Therapeutics after a rival's trial failure and after Trevi reported a slight Q2 loss and cash position.
Ticker impact
BMO reiterated an Outperform rating and $36 price target on Trevi Therapeutics after a rival's Phase 2b trial failed, and Raymond James raised its target to $40 following Trevi's own trial updates.
likely upward pressure as the market prices in the higher target and reduced competitive threat
The fresh competitor failure and multiple analyst target raises provide new, material information that could move the stock.
Market effects
The chronic cough biotech space may see re‑rating of peers as the competitor's failure reshapes competitive dynamics.
U.S. biotech investors may adjust exposure to cough‑related pipelines.
Limited to biotech sector; no broad market effect.
Counterpoint
If the competitor's failure signals broader challenges in cough therapeutics, Trevi could also face setbacks.
Key entities
- AnalystBMO Capital
Reiterated Outperform rating and $36 target.
- AnalystRaymond James
Raised price target to $40.
- CompetitorNocion
Phase 2b ASPIRE trial failed.
